New eczema drug shows promise: could injections be needed only every 3 months?
NCT ID NCT06526182
First seen May 01, 2026 · Last updated May 22, 2026 · Updated 5 times
Summary
This study tests the drug lebrikizumab in 520 adults and teens with moderate-to-severe eczema (atopic dermatitis). The first part looks at how well the drug improves skin symptoms after 24 weeks. The second part compares a new dosing schedule (one injection every 12 weeks) to the current schedule (every 4 weeks) to see if it works just as well. Participants must have had eczema for at least a year and have a certain level of skin severity to join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATITIS, ATOPIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Consorci Hospital General Universitari de València
Valencia, Spain
-
Hospital General Universitario Dr. Balmis
Alicante, Spain
-
Hospital Universitario Clínico San Cecilio
Granada, Spain
-
Hospital del Mar - Parc de Salut Mar
Barcelona, Spain
Conditions
Explore the condition pages connected to this study.